GH 리서치 (GHRS) 주가

GH 리서치(GHRS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $28.26 (-1.60%), 시가총액 $1.42B, 52주 최저~최고 $9.98 ~ $21.50.

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

핵심 지표

GH 리서치의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

GH 리서치 재무 요약

애널리스트 전망

핵심 재무비율 · 수익성 · 성장성

자주 묻는 질문

GH 리서치(GHRS) 현재 주가는 얼마인가요?

GH 리서치의 현재 주가는 $28.26 (-1.60%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.

GH 리서치(GHRS) 시가총액은 얼마인가요?

GH 리서치의 시가총액은 약 $1.42B입니다.

GH 리서치(GHRS)은 어떤 기업인가요?

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is